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Abstract
The last decade became the renaissance for investigating and exploring the potential role 
of immunotherapy in pediatric acute leukemia (AL). It is beyond question that there is 
an interaction between innate immune system and hematological malignancy. Leukemia 
cells inhibit the host immune response according to multiple mechanisms, but exploiting 
the innate immune system mechanisms can overcome the resistance to the conventional 
treatment. What is the role of immunotherapy in pediatric AL treatment? Does it have 
the potential to substitute or combine the standard chemotherapy? What is the best pos‐
sible timing to take advantage of immune interventions? This review is considered to fol‐
low through the possible treatment options including their foundation, strong and weak 
points, but also information about possible implementation into the clinical practice.
Keywords: immunotherapy, acute lymphoblastic leukemia, acute myeloblastic 
leukemia, children
1. Introduction
Acute leukemia (lymphoblastic and myeloblastic) is the most common malignancy diagnosed 
in children with an incidence of about 4.2 and 4.9 per 100,000 in the age groups of 0–19 and 
0–14, respectively. In the population of children aged 0–19, acute lymphoblastic leukemia 
(ALL) accounts for approximately 75% while acute myeloblastic leukemia (AML) accounts for 
20% of pediatric leukemia cases. Contemporary therapy allows achieving complete remission 
in approximately 90% of patients with ALL and 70% with AML [1, 2]. It is worth mentioning 
that 50 years ago acute leukemia was almost universally incurable [3]. The breakthrough has 
been achieved through standardized and optimized multi‐agent therapeutic regimens and 
through therapy individualization according to the risk stratification. However, even though 
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great progress in therapy is reported, refractory or relapsed leukemia remains one of the major 
causes of cancer‐related mortality. Failure to respond to chemotherapy is almost universally 
connected with poor prognosis. Survival rates for patients with relapsed or refractory AML 
receiving a second treatment attempt was estimated between 25 and 30% [4]. In 15% of ALL 
patients who experience relapse of the disease, long‐term survival rates vary from 40 to 50%, 
even though the remission is achieved in over 70% of patients [5, 6]. What is more, current che‐
motherapy regimens are consisted of very intensive blocks of treatment that are responsible 
for multiple acute and long‐term sequelae, especially in the pediatric population. According to 
multiple research, 60% of children after an anticancer treatment present at least one organ late 
effect [7]. New approaches that redirect treatment toxicity accurately to the neoplastic cells, 
sparing the normal cells and hematopoietic counterparts, will significantly reduce the possible 
complications and improve the survivor’s quality of life.
1.1. Contemporary treatment strategy for acute leukemia in children
The therapy for ALL and AML in children is based on standardized protocols and is com‐
posed of four major phases: remission induction, followed by consolidation, reinduction 
(intensification), and maintenance. In order to provide the most effective and harmless treat‐
ment for every patient, children are classified into three groups based on the risk of treatment 
failure (standard, intermediate, or high). This way, less toxic regimens can be administered 
to patients with more favorable prognosis, whereas those children with features showing 
higher risk of relapse are receiving more aggressive blocks of chemotherapy. Protocols that 
are currently used in treatment of acute leukemia in Polish children are ALL IC‐BFM 2009 and 
AML‐BFM 2012 [8, 9]. Allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which 
is a form of immunotherapy, is generally not recommended in the first remission of pediatric 
AML patients except for those at high risk. Comparably, only the children with high‐risk ALL 
and additional particular unfavorable prognostic factors, like T‐cell ALL, high initial leuko‐
cytosis, hypodiploidy, and genetic impairments, like t(9;22) or t(4;11), benefit from allo‐HSCT 
in the first complete remission [10, 11]. Radiotherapy is considered as a treatment option in 
case of extramedullary organ (central nervous system, testicular) involvement, but also as 
a prevention of central nervous system relapse in every patient with AML and, in strictly 
defined circumstances, children with the high‐risk ALL. This approach is reserved only for 
selected group of patients according to an increased risk and severity of ionization‐related 
late sequelae in the pediatric population [12].
Chemotherapy regimens used in acute leukemia in children are distinguished as extremely 
intensive, especially the treatment in patients with AML. This causes a long period of bone 
marrow aplasia that causes vulnerability to numerous infectious complications. Notably, 
5% of treatment failures using previous versions of chemotherapy regimens were the 
result of treatment‐related deaths in the first complete remission. According to the  significant 
improvement in supportive care and therapy individualization, the treatment‐related 
 mortality has decreased gradually over the last decade [13]. However, there are still patients 
with drug‐resistant or recurrent leukemia who require further efforts to identify effective 
treatment strategies based on the advances in our knowledge, understanding of leukemic cell 
biology, and interactions between them and the innate immune system. Without searching 
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for new approaches and confining ourselves only to chemotherapy regimens, their prognosis 
remains unfavorable.
1.2. Rationale for immunotherapy in acute leukemia
The evidence supporting the idea of interactions between immune system and malignant cells 
is based on multiple observations of leukemia course depending on immune system function. 
For example, shift reconstitution of the immune system after induction regimens correlates 
with improved survival, and absolute leukocyte count is an independent prognostic factor for 
survival in patients with acute leukemia [14]. What is more, it is proven that malignant cells 
use multiple pathways to interfere the host immune system promoting the number and func‐
tion of regulatory T cells (T regs) and subsequently reducing the ability of cytotoxic T cells to 
target leukemia [17].
The most popular and the only undisputed and thoroughly investigated form of immunother‐
apy, which has been applied in clinical practice for a few decades, is allogeneic HSCT. This form 
of treatment is considered in a subgroup of high‐risk patients in the first remission or in refrac‐
tory and relapsed hematological malignancies. The graft‐versus‐leukemia effect (GvL), which 
occurred to be an additional immunological benefit to this approach, is mediated by donor T 
cells and natural killer (NK) cells against residual leukemia blasts. This phenomenon was dis‐
covered according to the observations of a decreased risk of relapse in allogeneic graft recipients 
compared to patients after syngeneic HSCT or those who received T‐depleted grafts to reduce 
the risk of graft‐versus‐host‐disease (GvHD) [15].
Understanding the impact on immune response against malignant cells was a trigger to further 
investigations that enabled a better understanding of mechanisms of how leukemia cells man‐
age to evade immune surveillance. This study has laid the foundation for novel approaches 
using immune interventions. Immunotherapy approaches are mostly investigated in the con‐
text of HSCT. However, possible strategies are feasible also in settings which are not related 
to transplantation. The next chapter indicates the immunotherapeutic approaches that can be 
potentially implemented into the treatment regimens of acute leukemia in children (Table 1).
To boost the immunity
Inhibiting excessive function of regulatory T cells CTLA‐4 inhibition: Iipilimumab
PD‐1 inhibition: Nivolumab
To enhance the cytotoxic effect
Using T cells, NK cells, and dendritic cells Allogeneic HSCT
Donor lymphocyte infusion (DLI)
CAR‐T cell therapy
Transfer of allogeneic NK cells
CAR‐engineered NK cell therapy
Dendritic cell (DC) vaccines
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1.3. To boost the immunity: potential therapies inhibiting excessive function of regulatory 
T cells
Regulatory T cells’ (T reg, CD4+, CD25+) major role is to control immune tolerance. They are 
crucial to maintain unresponsiveness against self‐antigens, but also to prevent autoimmune 
diseases and allogeneic graft rejection. In terms of their role in hematological malignancies, 
they may suppress the anticancer effect mediated by activated T cells. As a consequence of 
tumor activity, their immunosuppressive effect on T cells may be aggravated compared to 
healthy individuals (Figure 1). Studies show that high plasma and tissue T regs level at the 
moment of diagnosis correlate with a worse response to chemotherapy and prognosis [16].
One of the mechanisms that leukemia cells tend to interfere T regs function is overexpression 
of the FOXP3 gene and high levels of Foxp3 mRNA, which is considered to be essential for 
their inhibitory effect. This phenomenon was described in particular subtypes of AML [17], 
but there are a few reports of Foxp3 overexpression and T regs activity in ALL. However, it 
Figure 1. Immune surveillance evasion of leukemic blasts by promoting T regs–inhibitory function.
To bridge the tumor cell to the killer
Monoclonal antibodies Anti‐CD20: Rituximab, Ofatumumab
Anti‐CD22: Epratuzumab
anti‐CD52: Alemtuzumab
anti‐CD33: Lintuzumab
Monoclonal antibodies conjugated to cytotoxic 
compounds
Anti‐CD22 linked to calicheamicin: Inotuzumab 
ozogamicin
Anti‐CD33 linked to calicheamicin: Gemtuzumab 
ozogamicin
Bispecific T‐cell engagers (BiTEs) Blinatumomab, anti‐CD3, and ‐CD19
Table 1. Immunotherapeutic strategies in acute leukemia.
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has been described that B‐ALL patients’ T regs presented higher immunosuppression than T 
reg cells from normal healthy individuals. What is more, chemotherapy corresponded to the 
reduction of Foxp3 and interleukin‐10 expression which is also a mediator of cytotoxic T cells 
suppression [18, 19].
Another way to support inhibitory T regs function mediated by leukemic blasts is the expres‐
sion of cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) on T cells and the surface of 
leukemia cells. CTLA‐4 binds the ligands which are essential for early T cell activation (CD80 
and CD86) and as a result it inhibits T cell activation and increases inhibitory cytokine produc‐
tion by T regs. It has been proved that the higher levels of soluble CTLA‐4 and CD86 in B‐ALL 
patients worsen the prognosis and should be considered as potential high‐risk factors [20, 21]. 
Inhibition of CTLA‐4 by specific antibody ipilimumab was not yet investigated in acute leuke‐
mia in children, but there are ongoing clinical trials assessing its potential in small groups of 
adults with acute myeloid leukemia, relapsed after allo‐HSCT showing promising regression 
of malignancy, but also immune‐related adverse events connected with drug infusion [22–24].
Programmed cell death protein 1 (PD‐1) high expression on activated immune system cells 
and Programmed cell death ligand 1 (PD‐L1) on blasts due to the tumor influence are mecha‐
nisms for leukemia evasion from an immune attack. This molecule induces T cell tolerance by 
direct inhibition of activated T cells and enhancement of T regs–inhibitory function in myeloid 
malignancies. Exhausted T cells are no longer capable to produce the cytokines: interleukin 
2 (IL‐2), tumor necrosis factor‐α (TNF‐α), and interferon‐γ (IFN‐γ), which impair their cyto‐
toxic effect. This is also the signal to induce the apoptosis of activated T cells. Overexpression 
of PD‐1 is associated with leukemia relapse after hematopoietic stem cell transplantation [25]. 
Using PD‐1 is being investigated as its inhibition (nivolumab) may have the potential to break 
immune tolerance to AML cells. It may also enhance the cytotoxic effect of donor‐derived 
cytotoxic T cells [26–28].
1.4. To enhance the cytotoxic effect: potential therapies are promoting innate or using 
adoptive T cells, NK cells, and dendritic cells
Donor lymphocyte infusion is the basic method of the relapse treatment and prevention after 
allogeneic HSCT mediated through the GvL effect. Its major complication was the high risk of 
graft‐versus‐host‐disease, which is associated with a donor lymphocyte reaction against host 
antigens [29]. Its efficacy is nonetheless assessed as disappointing. A major obstacle is tumor‐
mediated evasion from the immune surveillance by downregulating surface antigens and 
costimulatory molecules (CD80 and CD86). As a result, T cells are not appropriately activated 
in vivo to induce an antitumor response. To improve the efficacy of DLI, multiple methods 
have been used: costimulation with CD3/CD28 and activation ex vivo [30], enrichment of 
donor T cells with leukemia‐specific antigens (WT1) [31] or tumor‐specific and host‐restricted 
minor histocompatibility complex antigens [29, 32].
The DLI and GvL effect were the foundation to search for modified approaches to avoid 
side effects and use the potential T cells against leukemia. The next step was using geneti‐
cally modified and activated autologous T cells to target tumor‐specific antigens. The major 
advantage of this approach is eliminating the risk of GvHD.
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At first, genetic modifying was based on transferring α/β heterodimer of T‐cell receptors 
(TCRs) to the autologous T cells, but the limitation was the fact that the TCR receptor was only 
able to recognize antigens presented by human leukocyte antigen (HLA) molecules, which 
can be downregulated on the tumor cells avoiding immune surveillance. The next idea was 
to transfer chimeric antigen receptors (CARs) instead that are composed of a single‐chain‐
variable fragment (scFv) antibody, which is specific for tumor antigens. CARs have an ability 
to recognize and fight the cells presenting any specific antigen without HLA molecules. The 
engineered cells express antigen receptors against tumor‐associated surface antigens, thus 
redirecting the effector cells and enhancing tumor‐specific immunosurveillance [33].
CAR‐T cell therapy is now being actively investigated in refractory or relapsed ALL in adults 
and children. At the moment, majority of patients benefit from this approach having achieved 
remission when the disease appears to be incurable in terms of using standard chemotherapy. 
Side effects are mostly immune‐related and reversible. The studies were carried out on small 
groups of patients, and the results are now to be confirmed in the larger multicenter trials [34, 35].
The potential limitation that make a CAR‐T therapy ineffective in some groups of patients 
is the lack of the antigens that would be specific only for leukemia cells and their ability 
to downregulate the antigens by the neoplastic cells, but also unsatisfactory persistence of 
CAR‐T cells after an adoptive transfer and predominance of an immunosuppressive microen‐
vironment, which is a result of leukemia and the host immune system interactions [36].
One of the major challenges in terms of defining the ideal CAR‐T target antigen is identifying 
a leukemia‐specific molecule, expressed primarily, if not exclusively on the neoplastic cells, 
absent on their normal hematopoietic counterpart. This is an important field of research in 
terms of immunotherapy efficacy improvement [37]. The antigen that is commonly used as a 
target against B‐linear blasts is CD19; however, this molecule is not a specific one. Another tar‐
get that is being currently evaluated in a context of CAR‐T therapy in ALL is CD22. Targeting 
CD22 turned out to be effective in vitro and is currently investigated in vivo, but its expres‐
sion is still not limited to leukemia cells as this antigen is naturally presented by HLA class I 
on dendritic cells (DCs) and macrophages [38, 39]. In AML, CD33 is one of the most popular 
among various antigens that are being investigated. However, it is highly expressed on both 
leukemic cells and their normal hematopoietic counterpart which explains the severe toxicity 
of immunotherapy targeting CD33 established in the clinical trials [40]. CD123 molecule has 
emerged as more specific for AML blasts as it is expressed at low levels by normal progenitor 
cells, which makes it more applicable [41]. There is no defined target that could be addressed 
in the treatment of T‐linear ALL, which has a worse prognosis in the pediatric population 
compared to the B‐linear analog.
Further investigations led to multiple improvements of the method, like producing NK CAR 
cells as an alternative to T cells [42, 43], enhancing cytotoxicity of CAR‐T cells by the addition 
of costimulatory molecules (second and third generation) or by adding chemokine receptors 
to enable the effective infiltration to the tumor site. For example, the expression of CD40 ligand 
by genetically modified T cells leads to increased proliferation and secretion of proinflamma‐
tory TH1 cytokines, but also enhances the immunogenicity of tumor cells by upregulation of 
costimulatory molecules (CD80 and CD86), adhesion molecules (CD54, CD58, and CD70), 
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and human leukocyte antigen molecules on their surface. Improved survival was confirmed 
on a model with mice [44]. In terms of managing cytokine release syndrome, the researchers 
work on the antibody‐based switches to mediate the interaction between the CAR‐T cell and 
target cells to improve the safety of therapy [45].
In terms of using NK cells in the treatment of leukemia, a possible strategy is using adoptive 
transfer of allogeneic NK cells or genetically modified autologous NK cells (CAR‐engi‐
neered NK cells). Supremacy of NK cells over T cells is connected with its lower potential to 
cause GvHD while being donor‐derived [46, 47]. The limitation in using autologous NK cells 
is the overexpression of killer immunoglobulin‐like receptors (KIRs) on target cells which 
counteract the activation of the NK cells and tumor lysis. To overcome this problem, it is 
more accurate to use allogeneic NK cells, but it is also important to examine the donor and 
recipient in terms of incompatibility of the KIR ligand (which is presented with HLA‐Bw4 
and HLA‐C) [48]. Only mismatched donor’s NK cells would be effective in the treatment of 
residual disease. The efficacy of using adoptive immunotherapy with NK cells is being exam‐
ined in AML patients who are not eligible for stem cell transplantation. The results indicate 
that this approach can help to sustain the remission in patients with AML, but its efficacy is 
limited in active disease and it was only examined in a small group of elderly patients [46]. 
There are no reports in applying the therapy in patients with ALL.
Eliciting the T cells immunity can also be performed by using dendritic cell vaccines, which 
are modified to present antigens that are characteristic for leukemia blasts. This way, cyto‐
toxic T cells are activated to kill tumor cells overcoming the mechanisms of evading immune 
surveillance, like downregulating of surface antigens and then T regs function enhancement 
are present. DCs can be autologous or allogeneic, but the HLA restriction is essential for 
the second option. The specific antigen that has been used so far is Wilms’ Tumor‐1 (WT1), 
which is a characteristic for myeloblasts, especially in relapse, but it is also detectable in some 
patients with ALL and different solid tumors. This approach was assessed as effective in sev‐
eral patients with posttransplant‐relapsed AML or ALL. The GvHD was assessed as mild 
and no serious adverse events were reported [49–51]. Ongoing clinical trials are developed to 
assess WT1 dendritic cell vaccines in larger groups of patients.
1.5. To bridge the tumor cell to the killer
Antigens expressed on leukemic blasts can also be utilized as a target for specific antibodies. 
Hematological malignancies express surface molecules that are accessible in the circulation. 
Epitopes presented exclusively on leukemic cells would be preferential for the antibody ther‐
apy. However, identifying unique ones, characteristic only for the neoplastic cells and not for 
their normal hematopoietic counterparts, is challenging. There are several mechanisms that can 
be used to eliminate blasts including internalization of toxins or drugs that are conjugated to the 
antibodies, antibody‐dependent cellular toxicity (ADCC), complement‐dependent cytotoxicity 
(CDC), induction of apoptosis, and direct‐engaging endogenous T cells at the leukemic cells sur‐
roundings. Antigens that are candidates for antibody therapy in ALL are mostly characteristic 
for B‐linear differentiation, like CD19, CD20, and CD22, but it is necessary to look for the targets 
not only presented on B‐linear blasts, like CD52. Epitope that is targeted in AML is CD33 [52].
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Monoclonal antibodies (MoAbs) are capable of eliminating blasts not only by promoting 
cytotoxic or complement‐dependent cell lysis but also by blocking the effects that are advan‐
tageous for neoplastic cells, mediated by growth signals and various agonists. They are selec‐
tive to the targeted molecules so that the treatment‐related toxicity can be reduced. Also, 
the treatment response can be improved by using monoclonal antibodies as they sensitize 
leukemic blasts to the conventional chemotherapy. Their efficacy is generally limited when 
employed as a single agent, but in combination with the standard regimens they improve the 
overall survival even in chemoresistant or posttransplantation‐relapsed patients [53, 54].
CD20 was the first epitope that was successfully applied in the therapy of hematological 
malignancies. Rituximab is a chimeric monoclonal antibody, approved in 1997 by the Food 
and Drug Administration (FDA) in the treatment of non‐Hodgkin’s lymphoma and chronic 
lymphocytic leukemia, but its efficacy is also being assessed in combination with chemother‐
apy in adults with B‐cell acute lymphoblastic leukemia. In several studies, targeting CD20 was 
related to obtaining a prominent improvement of chemotherapy results in the Philadelphia 
chromosome‐negative BCP‐ALL [55–57]. Ofatumumab is also developed to target CD20; how‐
ever, its binding site is closer to the cell membrane and with greater avidity than rituximab. 
This second‐generation anti‐CD20 monoclonal antibody is considered to be more effective, 
even in patients who did not benefit from rituximab. Unconjugated monoclonal antibody that 
targets CD22 is called epratuzumab. Treatment with epratuzumab was assessed in combina‐
tion with conventional chemotherapy showing its feasibility in children with relapsed CD22‐
positive ALL. In several clinical trials, majority of patients achieved early responses [58, 59].
Alemtuzumab is a humanized monoclonal antibody against CD52. CD52 is expressed in 
about 50% of leukemia blasts, including B‐ and notably in T‐ALL and AML. It was assessed in 
small groups of patients in combination with granulocyte‐colony‐stimulating factor (G‐CSF) 
to boost antibody‐dependent cell cytotoxicity mediated by neutrophils showing transient 
good responses [60]. One of the promising monoclonal antibodies that can be potentially used 
in AML is anti‐CD33, lintuzumab [61, 62]. Clinical trials revealed high efficacy in the reduc‐
tion of leukemic blasts, but remissions were only reported after effective cytoreduction, not in 
patients with high tumor burden [63].
To improve leukemic‐targeted toxicity, we can also take one step further. If a target is known 
to internalize on binding, it is effective to use monoclonal antibodies conjugated to cyto‐
toxic compounds, producing an additional mechanism for cytotoxicity. For example, CD22 is 
proven to be internalized on antibody binding. Inotuzumab ozogamicin is the antibody tar‐
geting CD22 linked to calicheamicin that showed improvement over chemotherapy includ‐
ing complete hematologic remission, longer progression‐free, and overall survival [64, 65]. The 
analog that could have been potentially used in AML is gemtuzumab ozogamicin, targeting 
CD33. However, according to its toxicity and increased risk of veno‐occlusive disease (VOD), 
it has been withdrawn in 2010. Another approach using antibody‐dependent mechanisms of 
tumor cell lysis is using immunotoxins, which are recombinant anti‐CD22 or anti‐CD19 con‐
jugated with Pseudomonas or Diphtheria endotoxins. Radioimmunoconjugates are monoclo‐
nal antibodies linked to radioactive isotopes that can be beneficial as the part of hematopoietic 
stem cell transplantation regimens, but they are non‐preferential to be used in children.
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Bispecific T‐cell engagers (BiTEs) are designed to redirect and activate cytotoxic T cells 
precisely at the site of a tumor. The idea is to create antibody‐based constructs that tempo‐
rarily bridge T‐cells and cancer cells. The most popular and widely investigated bispecific 
antibody, Blinatumomab, targets CD3 and CD19. Based on multiple clinical studies that 
have shown an achievement of durable complete remission and acceptable safety profile, 
the FDA granted accelerated approval for blinatumomab for the treatment of Philadelphia 
chromosome‐negative relapsed or refractory B‐cell precursor acute lymphoblastic leukemia 
in 2014 [66–68]. AML treatment requires using BiTEs that are compatible to antigens on 
myeloblasts. AMG 330 is designed to target CD33 and CD3. Clinical studies indicate that 
this approach is efficient in relapsed AML, especially when combined with blockade of the 
PD‐1/PD‐L1 [26].
2. Conclusions
In the era of discovering new approaches to improve survival in childhood hematological 
malignancies, immunotherapy has a strong position. Potential benefits that can be achieved 
by implementation of highly active targeted therapies in pediatric acute leukemia are numer‐
ous. Improved overall survival and event‐free survival is the major advantage, but the pos‐
sibility to reduce treatment‐related toxicity is also extremely important for improving the 
convalescent’s quality of life. Treatment strategies are now actively investigated in multiple 
clinical trials, mostly in adults, but also in the pediatric population and the results are promis‐
ing. However, they can be evaluated only in situations when there are no longer better treat‐
ment strategies present in refractory or relapsed leukemia, which means that their efficacy is 
being assessed in desperate settings with high blasts burden and more aggressive neoplastic 
cells mutated according to the previous treatment [69]. It would be important to evaluate 
the role of immunotherapy combined with frontline regimens, whether this approach opti‐
mizes the treatment efficacy. For example, remission induction is the phase of impaired T regs 
number and function, which indicates that it is potentially beneficial to combine the T regs 
depletion with cytoreduction. What is more, it has been proven that the combination of dif‐
ferent immunotherapeutic strategies has the synergistic effect. T regs depletion with CAR‐T 
or bispecific antibodies straightens the efficacy of T cells cytotoxicity [26, 62].
There are still many challenges and difficulties to overcome to make the treatment of child‐
hood acute leukemia more effective and safe. Apart from numerous studies that provide 
a better understanding of the biology and genetics of leukemia, the impact of immuno‐
logical processes that influence the treatment response was underestimated for a couple 
of years. Significant breakthroughs achieved in immunotherapy that improved survival in 
patients with the most resistant disease triggered a renewed interest in this field of treat‐
ment. Immunotherapeutic strategies are being constantly improved using the advances 
of engineering techniques and a better understanding of immunological mechanisms that 
play a role in tumor surveillance. The assortment is impressive at the moment and is get‐
ting even wider, but it appears that in everyday clinical practice the opportunities are not 
adequately utilized.
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